India Share Brokers | Equity Trading India | Derivative Trading in India | Share Brokers in India

Markets Navigation

Company Info.

Marksans Pharma Ltd.

Income Statement - Consolidated

Market Cap.(`)	7561.04 Cr.	P/BV	4.33	Book Value (`)	38.51
52 Week High/Low ( ` )	186/71	FV/ML	1/1	P/E(X)	28.39
Book Closure	07/06/2023	EPS (`)	5.88	Div Yield (%)	0.30

(` in Crs.)

You can view the Consolidated Income Statement for the last 5 years.

Particulars	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Months	12	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR	AR
FaceValue	1.00	1.00	1.00	1.00	1.00


INCOME
Revenue From Operations [Net]	1849.62	1480.12	1368.37	1129.33	987.33
Other Operating Revenues	2.52	10.72	7.81	4.87	12.74
Total Operating Revenues	1852.14	1490.84	1376.18	1134.21	1000.07

Other Income	59.31	41.85	6.69	0.33	4.62
Total Revenue	1911.45	1532.69	1382.88	1134.54	1004.69

EXPENSES
Cost Of Materials Consumed	612.97	540.67	419.76	371.33	412.06
Purchase Of Stock-In Trade	314.78	163.25	311.57	120.60	105.85
Changes In Inventories Of FG,WIP And Stock-In Trade	-6.39	12.90	-136.28	52.95	-19.90
Employee Benefit Expenses	239.37	220.30	197.32	168.42	159.07
Finance Costs	9.13	8.45	7.99	8.75	9.66
Depreciation And Amortisation Expenses	51.85	44.78	36.15	26.66	22.80
Other Expenses	352.09	294.84	244.20	228.66	210.85
Total Expenses	1573.80	1285.18	1080.71	977.36	900.38

Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax	337.65	247.51	302.16	157.17	104.31

Profit/Loss Before Tax	337.65	247.51	302.16	157.17	104.31

Tax Expenses-Continued Operations
Current Tax	71.57	57.10	66.69	32.41	23.59
Deferred Tax	1.10	3.59	-3.07	4.47	1.00
Tax For Earlier Years	-0.33	0.01	0.00	-0.45	-0.72
Total Tax Expenses	72.33	60.70	63.63	36.42	23.87
Profit/Loss After Tax And Before ExtraOrdinary Items	265.32	186.81	238.54	120.75	80.44

Profit/Loss From Continuing Operations	265.32	186.81	238.54	120.75	80.44

Profit/Loss For The Period	265.32	186.81	238.54	120.75	80.44

Minority Interest	0.99	0.00	0.00	0.00	0.00
Consolidated Profit/Loss After MI And Associates	266.31	186.81	238.54	120.75	80.44

OTHER INFORMATION

EARNINGS PER SHARE
Basic EPS (Rs.)	6.41	4.51	5.76	2.86	1.87
Diluted EPS (Rs.)	6.41	4.51	5.76	2.86	1.87

DIVIDEND AND DIVIDEND PERCENTAGE
Equity Share Dividend	10.17	10.23	4.09	29.50	4.44
Preference Share Dividend	0.00	0.00	0.00	5.00	0.00

Marksans Pharma Ltd.

Balance Sheet - Consolidated

Market Cap.(`)	7561.04 Cr.	P/BV	4.33	Book Value (`)	38.51
52 Week High/Low ( ` )	186/71	FV/ML	1/1	P/E(X)	28.39
Book Closure	07/06/2023	EPS (`)	5.88	Div Yield (%)	0.30

(` in Crs.)

You can view the Consolidated Balance Sheet for the last 5 years.

Particulars	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Months	12	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR	AR
FaceValue	1.00	1.00	1.00	1.00	1.00
No. of Equity Shares (in Lacs)	4531.64	4093.14	4093.14	4093.14	4093.14

EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital	45.32	40.93	40.93	40.93	40.93
Preference Share Capital	0.00	0.00	0.00	0.00	10.00
Total Share Capital	45.32	40.93	40.93	40.93	50.93

Reserves and Surplus	1699.85	1161.34	845.56	595.08	501.55
Total Reserves and Surplus	1699.85	1161.34	845.56	595.08	501.55
Total Shareholders Funds	1745.16	1202.27	886.49	636.01	552.48
Minority Interest	19.91	20.70	18.86	13.11	10.22

NON-CURRENT LIABILITIES
Deferred Tax Liabilities [Net]	15.39	17.62	8.06	10.79	7.03
Other Long Term Liabilities	65.69	41.43	14.33	12.52	0.00
Long Term Provisions	3.25	1.86	2.11	1.47	1.36
Total Non-Current Liabilities	84.33	60.91	24.50	24.79	8.39

CURRENT LIABILITIES
Short Term Borrowings	41.59	41.29	18.74	18.84	99.91
Trade Payables	230.60	200.08	168.66	110.33	106.07
Other Current Liabilities	67.48	114.12	109.14	70.72	25.81
Short Term Provisions	1.33	0.72	1.85	28.86	0.84
Total Current Liabilities	340.99	356.22	298.40	228.75	232.62

Total Capital And Liabilities	2190.39	1640.10	1228.25	902.67	803.71

ASSETS
NON-CURRENT ASSETS
Tangible Assets	379.64	341.59	248.42	230.01	198.08
Intangible Assets	68.17	56.69	60.94	72.70	71.64
Capital Work-In-Progress	7.25	0.70	5.60	0.00	0.00
Intangible Assets Under Development	2.62	1.88	6.08	0.00	0.00
Fixed Assets	457.69	400.86	321.04	302.72	269.73
Goodwill On Consolidation	38.49	30.03	0.00	0.00	0.00
Deferred Tax Assets [Net]	0.00	3.86	0.80	0.63	1.25
Other Non-Current Assets	18.91	4.16	4.16	5.73	1.29
Total Non-Current Assets	515.09	438.90	326.00	309.08	272.27


CURRENT ASSETS
Current Investments	0.54	0.44	0.00	0.00	0.00
Inventories	484.74	424.44	404.32	241.84	293.25
Trade Receivables	416.85	394.78	271.38	243.35	176.60
Cash And Cash Equivalents	714.96	349.27	212.29	93.73	33.54
OtherCurrentAssets	58.21	32.28	14.26	14.67	28.06
Total Current Assets	1675.30	1201.20	902.25	593.59	531.44

Total Assets	2190.39	1640.10	1228.25	902.67	803.71

OTHER INFORMATION

CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities	9.31	17.02	19.78	48.17	30.40

Attention Investors : “Prevent unauthorized transactions in your account ? Update your Mobile Numbers/Email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your Mobile/Email at the end of the day. Issued in the interest of Investors” ***** No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. | | ***** KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. | "Revised guidelines on margin collection ==> 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. | 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | 3. Pay 20% upfront margin of the transaction value to trade in cash market segment. | 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. | 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors" | ***** MEMBERS : SEBI Regn. No: NSE, BSE: INZ000176636 ; MCX : INZ000057535; SEBI Research Analyst Regn No: INH200000337; AMFI Regn No. 77624; Depository Participant : CDSL : IN-DP-CDSL-379-2006 DP ID : 12047600 | For any Grievance mail to : grievance@sharewealthindia.com | For any DP Grievance mail to : dpgrievance@sharewealthindia.com. | Grievance with SEBI : https://scores.gov.in/scores/Welcome.html

Share Wealth

Marksans Pharma Ltd.

Income Statement - Consolidated

Marksans Pharma Ltd.

Balance Sheet - Consolidated